We are live on ! Find out more
MGRX icon

Mangoceuticals

8 hedge funds and large institutions have $147K invested in Mangoceuticals in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

0.64% less ownership

Funds ownership: 3.67% → 3.02% (-0.64%)

11% less funds holding

Funds holding: 9 → 8 (-1)

34% less capital invested

Capital invested by funds: $221K → $147K (-$74.1K)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
8
Holders Change
-1
Holders Change %
-11.11%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

MGRX Hedge Fund Activity: Q1 2025 in Review

8 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Mangoceuticals (MGRX) for Q1 2025, worth a combined $147K — down 34% from $221K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of MGRX and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 4 added.

The largest buyer was Geode Capital Management, adding an estimated $27.2K. The largest seller was Virtu Financial, exiting entirely with an estimated $50K sold.

  • 8 institutional investors held Mangoceuticals (MGRX) as of Q1 2025, down from 9 in Q4 2024.
  • Funds reported $147K of Mangoceuticals stock for Q1 2025, down 34% quarter-over-quarter.
  • 1 fund opened new Mangoceuticals positions in Q1 2025 and 2 closed out, a net change of -1 holder.
  • The largest Mangoceuticals buyer in Q1 2025 was Geode Capital Management, an estimated $27.2K added.
  • The largest Mangoceuticals seller in Q1 2025 was Virtu Financial, an estimated $50K sold.

Based on aggregated 13F filings for Q1 2025.